Gene: APOLD1
Official Full Name: apolipoprotein L domain containing 1provided by HGNC
Gene Summary: APOLD1 is an endothelial cell early response protein that may play a role in regulation of endothelial cell signaling and vascular function (Regard et al., 2004 [PubMed 15102925]).[supplied by OMIM, Dec 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO25730 | APOLD1 Knockout cell line (HeLa) | Human | APOLD1 | 1:3~1:6 | Negative | Online Inquiry |
KO25731 | APOLD1 Knockout cell line (HCT 116) | Human | APOLD1 | 1:2~1:4 | Negative | Online Inquiry |
KO25732 | APOLD1 Knockout cell line (HEK293) | Human | APOLD1 | 1:3~1:6 | Negative | Online Inquiry |
APOLD1 Gene Knockout Cell Lines are specialized cellular systems genetically engineered to lack the expression of the APOLD1 gene, which encodes for a protein involved in angiogenesis and endothelial function. These cell lines serve as powerful tools for researchers investigating the molecular mechanisms underpinning various biological processes, particularly those related to vascular biology and cellular responses to hypoxia or inflammation.
The key function of APOLD1 Gene Knockout Cell Lines lies in their ability to elucidate the role of APOLD1 in physiological and pathological contexts. By selectively deleting the APOLD1 gene, researchers can observe changes in cellular behavior, signaling pathways, and gene expression patterns, allowing for a more granular understanding of the gene's contribution to health and disease. This genetic manipulation also facilitates the assessment of potential therapeutic targets associated with vascular disorders and cancer.
The scientific importance of these cell lines is underscored by their applications in both basic research and translational studies. They offer an invaluable model for studying endothelial cell dynamics, drug responses, and the effects of genetic alterations on cellular function. In clinical settings, APOLD1 Gene Knockout Cell Lines can aid in the development and testing of novel therapeutic approaches aimed at diseases linked to dysfunctional angiogenesis.
Compared to conventional cell lines, the APOLD1 Gene Knockout variants provide specificity and clarity in experimental outcomes, effectively reducing background noise associated with gene expression. Their unique ability to mimic in vivo conditions makes them superior for detailed mechanistic studies. Furthermore, these cell lines are ideal for high-throughput screening processes, enhancing their utility in drug discovery and personalized medicine applications.
The value of APOLD1 Gene Knockout Cell Lines is evident in their capacity to accelerate scientific discovery and improve the understanding of complex biological systems. Researchers, clinicians, and pharmaceutical developers can leverage these models to unlock new insights and potential interventions in diseases that currently pose significant challenges.
Our company is committed to advancing scientific research by providing high-quality biological products, including our meticulously crafted gene knockout cell lines. With a dedicated team of experts, we ensure that our offerings are rigorously validated and optimized for a wide range of applications in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.